Evidence map›Paper›PMID 28864675›Full record

Trial reportNeurology2017

Causal inference methods to study gastric tube use in amyotrophic lateral sclerosis.

Erin McDonnell, David Schoenfeld, Sabrina Paganoni, Nazem Atassi

Registry-linked trialAbstract readMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in Neurology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00349622 (Clinical Trial Ceftriaxone in Subjects With Amyotrophic Lateral Sclerosis), which is not on this map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00349622 phase3completednot on this map

Clinical Trial Ceftriaxone in Subjects With Amyotrophic Lateral Sclerosis (ALS)

TypeinterventionalSponsorMassachusetts General HospitalRan2006 to 2012Enrolled513ConditionsAmyotrophic Lateral Sclerosis, ALSArmsceftriaxone, placebo
3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 22 citations in OpenAlex.

  1. Observational
  2. Review
  3. Tofersen for SOD1 ALS.Neurodegenerative disease management · 2024
    Review
  4. Enteral tube feeding for amyotrophic lateral sclerosis/motor neuron disease.The Cochrane database of systematic reviews · 2023
    Review
  5. Article
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Erin McDonnellFrom the Biostatistics Center (E.M., D.S.) and Neurological Clinical Research Institute (S.P., N.A.), Massachusetts General Hospital; and Harvard Medical School (D.S., S.P., N.A.), Boston, MA. EIM726@mail.harvard.edu NAtassi@mgh.harvard.edu.
David SchoenfeldFrom the Biostatistics Center (E.M., D.S.) and Neurological Clinical Research Institute (S.P., N.A.), Massachusetts General Hospital; and Harvard Medical School (D.S., S.P., N.A.), Boston, MA.
Sabrina PaganoniFrom the Biostatistics Center (E.M., D.S.) and Neurological Clinical Research Institute (S.P., N.A.), Massachusetts General Hospital; and Harvard Medical School (D.S., S.P., N.A.), Boston, MA.
Nazem AtassiFrom the Biostatistics Center (E.M., D.S.) and Neurological Clinical Research Institute (S.P., N.A.), Massachusetts General Hospital; and Harvard Medical School (D.S., S.P., N.A.), Boston, MA.
Harvard University · US

Funding

Clinical Trial of Ceftriaxone in Subjects with ALSU01NS049640 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · PI CUDKOWICZ, MERIT E · 2006 to 2012
$37.7M
NINDS NIH HHS U01 NS049640
6 · The paper itself

Abstract

objectiveTo estimate effects of gastric tube (G-tube) on survival and quality of life (QOL) in people with amyotrophic lateral sclerosis (ALS) correcting for confounding by indication inherent in nonrandomized observational data.

methodsTo complement a recent causal inference analysis, which concluded that G-tube placement increases the hazard of death, permanent assisted ventilation, or tracheostomy by 28%, we fit causal inference models on a different sample of 481 patients with ALS enrolled in a recent clinical trial of ceftriaxone. Forward selection identified predictors of G-tube placement. Effects of G-tube on survival and QOL were estimated using structural nested models and marginal structural models, accounting for predictors of G-tube treatment.

resultsForced vital capacity and the total score and bulbar subscale of the revised ALS Functional Rating Scale best predicted G-tube placement. Correcting for these confounders, G-tube placement decreased survival time by 46% (

conclusionsIn the absence of randomization, causal inference methods are necessary to correct for time-varying confounding. G-tube placement may have a negative effect on survival with no QOL-related benefit for people with ALS. A randomized controlled trial is warranted to further evaluate the efficacy of this widely used intervention. CLINICALTRIALSGOV IDENTIFIER: NCT00349622. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that for patients with ALS, G-tube placement decreases survival time and does not affect QOL.

Indexed as

Quality of LifeSurvivalAdultAgedAmyotrophic Lateral SclerosisDisease ProgressionEnteral NutritionFemaleFollow-Up StudiesHumansMaleMiddle AgedRespiration, ArtificialSurvival AnalysisVital Capacity

Identifiers

PMID28864675
PMCPMC5631169
OpenAlexW2753836043

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.